GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Mkt Perform
ALKS

Alkermes, Inc. (ALKS) rated Mkt Perform with price target $31 by FBR Capital

Posted on: Wednesday,  Oct 30, 2013  8:25 AM ET by FBR Capital

Alkermes, Inc. (NASDAQ: ALKS) rated
Mkt Perform with price target $31 by FBR Capital.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

FBR Capital uses a highly disciplined analysis focused on intrinsic value, which we developed to critically examine the capital structure of the companies we cover, as well as their competitive positions and the growth opportunities within their industries. We apply this discipline – which helps us assess how effectively a company’s managers deploy the capital entrusted to them – not only in our published research but also when making investing and underwriting judgments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2013 8:25 AM Hold
None
36.06 31.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy